The citrus flavonoid and vitamin B12 manufacturer announced the construction of a new diosmin production plant at its research, development and manufacturing center in Murcia, Spain.
“Our new plant will not only increase production, it will also equip us to improve our operating model through research-driven process innovation, digitalization and energy efficiency,” said Ignacio Paco Ferreira, chief operations officer at HTBA.
Water-based diosmin manufacturing
Diosmin, a plant-derived flavonoid found mainly in citrus fruits, is best known for its role in vein and circulation health.
HTBA currently manufactures diosmin as a pharmaceutical ingredient for the treatment of chronic cardiovascular disease (CVD), varicose veins, spider veins and hemorrhoids, as well as its branded ingredient DiosVein, that can be incorporated into gummies, powders and softgels.
Conventional diosmin production typically relies on chemical synthesis or semi-synthetic processes that use solvents such as pyridine during extraction or conversion steps. These solvents improve manufacturing efficiency but require extensive purification to remove residual chemicals and meet safety specifications. The resulting diosmin often varies in particle size and therefore may need to undergo additional processing, such as milling or micronization, to improve handling and bioavailability.
However, as Alexandre Valls-Coma, CEO at HTBA, told NutraIngredients, HTBA uses a water-based process to produce diosmin, reducing the risk of solvent residues and supporting high standards of safety and purity.
“This approach also produces a highly stable ingredient, with a shelf life of up to five years, and the precise particle control achieved through micronization delivers superior absorption and functional versatility, making it easier to incorporate into complex supplement formulations,” he said.
Why diosmin demand is surging
Diosmin has been found to help manage conditions like Chronic Venous Insufficiency (CVI), ease leg heaviness and reduce pain, restless legs and evening swelling. Research shows it can help maintain vascular elasticity and slow venous wall deterioration, thereby acting as an anti-oxidant and anti-inflammatory agent."
“The need for solutions like this is especially high among older adults, whose CVD risk doubles after 60, and women, who are more affected by hormonal factors like pregnancy or estrogen therapy,” Valls-Coma said.
Aging populations, sedentary work, obesity, pregnancy and long hours of sitting or standing are driving higher rates of chronic venous insufficiency, varicose veins and leg discomfort.
“Interest in ingredients—like diosmin—that boost venous tone and circulation is surging,” Valls-Coma said, citing data from DataIntello that suggests the global circulation support supplements market is projected to grow by 7% by 2030.
“With CVD estimated to affect over a quarter of the adult population globally, awareness of vascular health as a pillar of ‘healthspan’ is growing and more consumers are looking for non-invasive, science-backed solutions,” he noted.
“When it comes to maintaining mobility as we age, diosmin acts like a ‘chemical compression stocking,’ easing leg pain and swelling so users can stay on their feet longer and embrace an active lifestyle without discomfort.”
As consumers seek to improve healthspan, diosmin is shifting from a ‘reactive pharmaceutical treatment’ to a ‘proactive nutraceutical star’, Valls-Coma said.
